IP Library › Granted Patent US 12,698,306
Granted Patent B2
US 12,698,306 · App. 17/795,426 · Granted Aug 4, 2026

Bile acid-GCPII inhibitor conjugates to treat inflammatory diseases, including inflammatory bowel disease (IBD)

Inventors: Barbara Slusher (Baltimore, MD); Diane E. Peters (Baltimore, MD); Rana Rais (Baltimore, MD); Pavel Majer (Prague, CZ); Lukas Tenora (Prague, CZ); Ivan Snajdr (Prague, CZ)
Assignees: The Johns Hopkins University; Institute of Organic Chemistry & Biochemistry as CR V.V.I.
C07J51/00A61P29/00C07J33/002C07J41/0055
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,698,306
App. No.
17/795,426
Filed
Jul 26, 2022
Granted
Aug 4, 2026
Kind
B2
Art Unit
1624
USPC
514/121
Abstract

GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.

Claims (7)

1 . A compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

2 . A method for treating a disease or condition associated with an elevated GCPII activity in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof wherein the disease or condition associated with an elevated GCPII activity is an inflammatory bowel disease.

3 . The method of claim 2 , wherein the inflammatory bowel disease is selected from the group consisting of Crohn's disease (CD) and ulcerative colitis (UC).

4 . The method of claim 2 , wherein the method for treating a disease or condition associated with an elevated GCPII activity inhibits GCPII activity in the subject.

5 . A pharmaceutical composition, comprising at least one compound of claim 1 , in admixture with a pharmaceutically acceptable excipient.

6 . The pharmaceutical composition of claim 5 , further comprising one or more additional therapeutic agents.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ERROR IN ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 62145 FRAME 793. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded May 28, 2026
From: MAJER, PAVEL; TENORA, LUKAS; SNAJDR, IVAN
To: INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY AV CR V.V.I.
Reel/Frame 075643/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: SLUSHER, BARBARA; PETERS, DIANE E; RAIS, RANA
To: THE JOHNS HOPKINS UNIVERSTY
Reel/Frame 062145/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: TENORA, LUKAS; SNAJDR, IVAN; MAJER, PAVEL
To: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
Reel/Frame 062145/0793 →
Continuity (2)
Provisional Application 62968602 · Jan 31, 2020
Related Publication 20230128984A1 · Apr 27, 2023
References Cited (64)
US 9220265B2 · Hoekstra et al. · 2015 [cited by applicant]
US 10105415B2 · Heslet et al. · 2018 [cited by applicant]
US 10172921B2 · Couvineau et al. · 2019 [cited by applicant]
US 20110064657A1 · Pomper et al. · 2011 [cited by applicant]
US 20160095921A1 · Ebsworth et al. · 2016 [cited by applicant]
US 20160289262A1 · Wang et al. · 2016 [cited by applicant]
US 20180180630A1 · Monteleone · 2018 [cited by applicant]
JP H0995496A · 1997 [cited by applicant]
JP 2010517931A · 2010 [cited by applicant]
JP 2017533923A · 2017 [cited by applicant]
JP 2017535570A · 2017 [cited by applicant]
JP 2017536379A · 2017 [cited by applicant]
JP 2020525426A · 2020 [cited by applicant]
WO WO2002092553 · 2002 [cited by applicant]
WO WO2004078742 · 2004 [cited by applicant]
WO WO2016022809 · 2016 [cited by applicant]
WO WO2016022827 · 2016 [cited by applicant]
Fini et al. (Archiv der Pharmazie, 320(10), 1014-1019). (Year: 1987). [cited by examiner]
O'Brien (Polymer Engineering and Science, 29(13), 846-849). (Year: 1989). [cited by examiner]
Extended EP Search Report for EP21747380.0, mailed Mar. 7, 2024, 5 pages. [cited by applicant]
Wu et al., Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry Letters, vol. 18, No. 1, Oct. 30, 2007, pp. 281-284. [cited by applicant]
International Search Report and Written Opinion for PCT/US2021/015732. Mailed Apr. 15, 2021. 10 pages. [cited by applicant]
Baldwin et al., Neuroinflammation triggered by ß-glucan/dectin-1 signaling enables CNS axon regeneration. Proc Natl Acad Sci U S A. Feb. 24, 2015;112(8):2581-6. [cited by applicant]
Berge et al., Pharmaceutical salts. J Pharm Sci. Jan. 1977;66(1):1-19. [cited by applicant]
Calmus et al., Shaping macrophages function and innate immunity by bile acids: mechanisms and implication in cholestatic liver diseases. Clin Res Hepatol Gastroenterol. Oct. 2014;38(5):550-6. [cited by applicant]
Colombel et al., Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. Jan. 2007;132(1):52-65. [cited by applicant]
Coskun et al., Novel Targeted Therapies for Inflammatory Bowel Disease. Trends Pharmacol Sci. Feb. 2017;38(2):127-142. [cited by applicant]
Ferraris et al., Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors. Current Medicinal Chemistry, 2012, 19(9), 1282-1294. [cited by applicant]
Greene et al., Protective Groups in Organic Synthesis, 3rd ed. John Wiley & Sons. 1999. TOC only. 3 pages. [cited by applicant]
Hamilton et al., Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol. Jan. 2012;47(1):1-8. [cited by applicant]
Hanauer et al., Maintenance infliximab for Crohn's disease: the Accent I randomised trial. Lancet. May 4, 2002;359(9317):1541-9. [cited by applicant]
Hazra et al., Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals. Bioorg Med Chem Lett. Feb. 9, 2004;14(3):773-7. [cited by applicant]
Ho et al., Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. Feb. 9, 2016;113(6):1600-5. [cited by applicant]
Jackson et al., Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem. Nov. 22, 2001;44(24):4170-5. [cited by applicant]
Jackson et al., Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem. Jan. 19, 1996;39(2):619-22. [cited by applicant]
Kaser et al., Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621. [cited by applicant]
Kozuch et al., Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. Jan. 21, 2008;14(3):354-77. [cited by applicant]
Kuehne et al., Steroidal Dihydro-1,3-Oxazines as Antitumor Agents. J Med Pharm Chem. Mar. 1962;5:281-96. [cited by applicant]
Kull et al., Mixturs of quaternary ammonium compounds and long- chain fatty acids as antifungal agents. Appl Microbiol. Nov. 1961;9(6):538-41. [cited by applicant]
Laukens et al., Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. Lab Invest. Dec. 2014;94(12):1419-30. [cited by applicant]
Lawrance. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol. Feb. 7, 2014;20(5):1248-58. [cited by applicant]
Li et al., Synthesis, Anticancer Activities, Antimicrobial Activities and Bioavailability of Berberine-Bile Acid Analogues. Lett. Drug Des. Discov. 2012, 9(6), 573-580. [cited by applicant]
Mesters et al, Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. The EMBO Journal. 2006;25,1375-1384. [cited by applicant]
Mostarda et al., Glucuronidation of bile acids under flow conditions: design of experiments and Koenigs-Knorr reaction optimization. Org Biomol Chem. Dec. 21, 2014;12(47):9592-600. [cited by applicant]
Nedelcovych et al., Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs. Mol Pharm. Oct. 2, 2017;14(10):3248-3257. [cited by applicant]
Nedelcovych et al., Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders. J Neuroimmune Pharmacol. Sep. 2019;1… [cited by applicant]
Pellicciari et al., Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid… [cited by applicant]
Rais et al., FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight. Aug. 4, 2016;1(12):e88634. 11 pages. [cited by applicant]
Regueiro et al., Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. Sep. 2007;13(9):1093-9. [cited by applicant]
Robinson et al., Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem. Oct. … [cited by applicant]
Rojas et al., Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem. Nov. 1, 2002;310(1):50-4. [cited by applicant]
Rubin and Farber, Pathology. J.B. Lippincott Company. 1994. TOC only. 4 pages. [cited by applicant]
Sartor et al., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. Jul. 2006;3(7):390-407. [cited by applicant]
Schmidt et al., Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis. Jan. 2007;13(1):65-70. [cited by applicant]
Schreiber et al., Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. Jul. 19, 2007;357(3):239-50. [cited by applicant]
Sievanen. Exploitation of Bile Acid Transport Systems in Prodrug Design. Molecules, 2007, 12, 1859-1889. [cited by applicant]
Sipka et al., The immunomodulatory role of bile acids. Int Arch Allergy Immunol. 2014;165(1):1-8. [cited by applicant]
Slusher et al, Glutamate Carboxypeptidase II. Handbook of Proteolytic Enzymes vol. 2, 2013, pp. 1620-1627. [cited by applicant]
Strober et al., The fundamental basis of inflammatory bowel disease. J Clin Invest. Mar. 2007;117(3):514-21. [cited by applicant]
Tang et al., Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. Biochem Biophys Res Commun. Jul. 18, 2003;307(1):8-14. [cited by applicant]
Van Assche et al., Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. Jul. 28, 2005;353(4):362-8. [cited by applicant]
Vitharana et al., Synthesis and biological evaluation of (R)- and (S)-2-(phosphonomethyl)pentanedioic acids as inhibitors of glutamate carboxypeptidase II., Tetrahedron: Asymmetry., 2002; vol. 13(15), pp. 1609-1614. [cited by applicant]
Xavier et al., Unravelling the pathogenesis of inflammatory bowel disease. Nature. Jul. 26, 2007;448(7152):427-34. [cited by applicant]
Yadav et al., Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Transl Res. Oct. 2016;176:38-68. [cited by applicant]